To our greatest regret CiMaas has filed for bankruptcy, which became effective Tuesday June 11, 2024. Although CiMaas has great assets in the field of NK cell immunotherapy for cancer using its proprietary feeder cell technology and expansion methodology, it was unable to raise enough financial resources to perform the required clinical studies.
Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells. Conversely, CYTEA BIO will supply CiMaas with Pin™ antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.
The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell therapy medicinal product with the indication for acute myeloid leukaemia.
Recently 1085 companies were invited to submit a full proposal – based on a first screening – to apply for an EIC accelerator grant. Of them only 42 were granted (3,8%). A seal of excellence was given to 193 (17,8%), including CiMaas. CiMaas received another opportunity to defend its proposal for the EIC council in… Read more »
Upon rigorous analysis, our research has demonstrated that this innovative feeder cell approach results in an enhanced proliferation rate for NK cells compared to the traditional method employing irradiated feeder cells. Remarkably, within a mere week, a 100-fold expansion rate is already achieved, with the potential for ongoing expansion. After 12 days we reach 19… Read more »
Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics’ proprietary Tumor Glycoform specific scFv discovery platform and CiMaas’s Adoptive CAR-NK technology.
Post
CiMaas filed patent application on feeder cell preparation in support of its NK cell therapy program
CiMaas has filed a new patent application on a new method for the feeder cell preparation in support of its NK cell therapy program. Treatment with Natural Killer (NK) cells is the CiMaas strategy to potentially cure patients with cancer. CiMaas uses a feeder cell based NK cell expansion protocol to generate high NK cell… Read more »
CiMaas BV announces that it has created a GMP grade master cell bank of the F012 feeder cell line to support Natural Killer (NK) cell expansion isolated from peripheral blood cells. CiMaas had generated a feeder cell line containing two genes that induce NK cell proliferation and maturation resulting in NK cells with a memory… Read more »
CiMaas’ leading product to fight cancer is Natural Killer (NK) cells. These cells kill tumor cells directly as has been observed in pre-clinical studies, as well as in clinical studies (patients with myeloid leukemia). To obtain a large number of these NK cells to treat patients, so-called feeder cells are needed to stimulate the proliferation… Read more »
By entering into a research collaboration with an option for an exclusive commercial license for its antibody structures (specific directed against underglycosylated Mucin-1 and potentially other candidates) to CiMaas, the Technical University of Denmark (DTU) and CiMaas have strengthened their relation to fight cancer.